Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Gilead and GSK go head...

    Gilead and GSK go head to head with similar HIV drug data

    Written by Ruby Khatun Khatun Published On 2017-06-01T09:42:27+05:30  |  Updated On 1 Jun 2017 9:42 AM IST
    Gilead and GSK go head to head with similar HIV drug data
    Gilead Sciences Inc and GlaxoSmithKline Plc (GSK) will go head-to-head with rival versions of an improved class of HIV medicines, after clinical studies showed the U.S. company's new drug bictegravir was as effective as GSK's product.

    Four late-stage studies from Gilead all met their goals, with bictegravir matching the efficacy of GSK's established dolutegravir, which has been the cornerstone of the British group's growing HIV business in recent years.


    Both drugs are so-called integrase inhibitors, a type of medicine that has proved extremely effective at blocking the AIDS virus. They are designed to be given alongside older antiretroviral therapies.


    In a statement on Tuesday, Gilead said drug combinations testing bictegravir had proved equally good, or "non-inferior", to combinations using dolutegravir, as measured by their ability to suppress levels of HIV.


    The news confirms a looming competitive threat to GSK's important ViiV Healthcare business, but it also suggests the balance may not tip overwhelmingly in favor of Gilead.


    Gilead shares were little changed, while GSK rose 1.8 percent in London as Deutsche Bank analysts said the news "alleviates a small risk that bictegravir would have superior efficacy to dolutegravir".


    The results are nonetheless a success for California-based Gilead, which Berenberg analysts said was likely to take a meaningful portion of growth in the HIV treatment market, with annual bictegravir sales reaching $3.8 billion by 2020.


    Gilead plans to apply this year for regulatory approval to sell its combination of bictegravir and emtricitabine/tenofovir alafenamide (FTC/TAF), with a submission in the United States in the second quarter and Europe in the third quarter.


    If Gilead uses a priority voucher at the U.S. Food and Drug Administration, it could launch in the U.S. market in the first quarter of 2018, some industry analysts said.


    For a long time Gilead has dominated the HIV market but GSK fought back strongly with dolutegravir, which has been a star performer recently.


    Now Gilead is hoping to reaffirm its dominance with its new three-drug combination based around bictegravir. GSK, meanwhile, is working on a two-drug treatment regimen.


    Three of Gilead's studies tested its combination against a regimen containing GSK's dolutegravir in previously untreated patients. The fourth trial included patients who were already on HIV therapies, but were switched to the Gilead combination.


    Data showed the Gilead combination was as effective and also well tolerated. No patients discontinued treatment due to kidney problems, a common side effect seen with HIV treatments.


    Antiretroviral therapy has turned HIV from a death sentence into a manageable condition but patients need to stay on treatment for life, so there is a growing focus on making medication as well-tolerated as possible.


    (Reporting by Ben Hirschler and Akankshita Mukhopadhyay; Editing by Sriraj Kalluvila, editing by David Evans)

    AIDSbictegravirDolutegravirGilead SciencesGilead Sciences IncGlaxoSmithKlineGlaxoSmithKline PlcGSKHIVHIV medicinespharma news
    Source : REUTERS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok